2 reports of this reaction
3.6% of all CALENDULA OFFICINALIS reports
#2 most reported adverse reaction
ERYTHEMA is the #2 most commonly reported adverse reaction for CALENDULA OFFICINALIS, manufactured by Seroyal USA. There are 2 FDA adverse event reports linking CALENDULA OFFICINALIS to ERYTHEMA. This represents approximately 3.6% of all 56 adverse event reports for this drug.
Patients taking CALENDULA OFFICINALIS who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is moderately reported among CALENDULA OFFICINALIS users, representing a notable but not dominant share of adverse events.
In addition to erythema, the following adverse reactions have been reported for CALENDULA OFFICINALIS:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 2 FDA reports for CALENDULA OFFICINALIS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 3.6% of all adverse event reports for CALENDULA OFFICINALIS, making it one of the most commonly reported side effect.
If you experience erythema while taking CALENDULA OFFICINALIS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.